Roivant Sciences Ltd. (ROIV) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Roivant Sciences Ltd. (ROIV) advanced +1.11% to $37.52 as options desks priced 60% call premium vs. 40% put protection around the $37 max-pain magnet. Solid 41% profit margin (-14% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Today Roivant Social Ventures (RSV) announced it is joining efforts with No Patient Left Behind (NPLB) to improve drug affordability and access while supporting ongoing medical
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 26.86% on an annualized basis producing an average annual return of 37.68%. Currently, Roivant Sciences has a market capitalization of
2026-10-24. The following slide deck was published by Roivant Sciences Ltd.
Key TakeawaysRoivant shares jumped 8% today after brepocitinib met the main goal and every key secondary goal in two Phase 3 trials in non-infectious uveitis. The results make uveitis a likely second use for a drug alrea
Roivant Sciences (NASDAQ:ROIV) reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflammatory
Roivant (ROIV) shares jump as Phase 3 CLARITY trials show brepocitinib effectively treats noninfectious uveitis & reduces steroid reliance.
Investing.com -- Roivant Sciences Ltd (NASDAQ:ROIV) shares jumped 9% in premarket trading Wednesday after the company announced brepocitinib met all Phase 3 endpoints in trials for non-infectious uveitis.
Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials comprising
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ROIV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ROIV. Explore sector supply chains on /butterfly.
Why ROIV Stock advanced +1.11% Today — RQD Quant Desk Flash. Solid 41% profit margin (-14% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.